Hypercoagulable states, heritable coagulopathies (e.g., factor V Leiden mutation, protein S deficiency, and antiphospholipid syndrome), infectious etiologies (e.g., sepsis, COVID-19), and solid tumor malignancies are all known to contribute to TAMT [4,13-16]. This evidence concerns the gene F5 and COVID-19.